Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/TG Therapeutics posts strong revenue growth but misses EPS estimates in Q2 2026 earnings.
TGTX
$46.20
-$5.83 -11.21%

TG Therapeutics posts strong revenue growth but misses EPS estimates in Q2 2026 earnings.

Company Fundamentals
03 Aug 2026
Tony Dante
View Source
Neutral
pluang ai news

TG Therapeutics reported mixed Q2 2026 results with total revenue of $240.34 million, beating estimates thanks to strong sales of its drug BRIUMVI, which grew over 64% year-over-year. However, earnings per share (EPS) came in at $0.05, significantly below the expected $0.31 and down from $0.17 a year ago. The company raised its full-year 2026 revenue guidance to about $950 million, reflecting confidence in continued sales growth despite the profit miss. Investors should watch how the company manages profitability alongside expanding market adoption of BRIUMVI.

More News (TGTX)

TG Therapeutics raises 2026 revenue guidance after strong Q2 with BRIUMVI sales hitting $228M in the U.S.

TG Therapeutics raises 2026 revenue guidance after strong Q2 with BRIUMVI sales hitting $228M in the U.S.

TG Therapeutics reported strong second quarter 2026 results with total global revenue of approximately $240 million, including $228 million in U.S. net product revenue from BRIUMVI. The company raised its full year 2026 revenue guidance to about $950...

Company Fundamentals
Bullish
10 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App